MediWound debuts strongly

IPO MediWound (MDWD) closes at $17.27 up 23% today on 4.2M shares giving it a market cap of $364M.

The Israel-based biopharmaceutical company focuses on severe burns, chronic and hard-to-heal wounds and connective tissue disorders.

Its lead product, NexoBrid, is a topical gel for the removal of eschar (debridement).

The firm launched NexoBrid in Europe in December 2013.

A phase 3 clinical trial will commence in the U.S. by June.

No sales as of year end.

Operations burned $8M in 2013.

From other sites
Comments (1)
  • Joe McCann
    , contributor
    Comments (268) | Send Message
    After a nice IPO that I barely got any allotment in (50 shares...) I'm looking to do a project to really understand the company's lead product, using Slingshot Insights. Check it out and see if you're interested in joining:



    2 months free membership with the coupon code: 2mos_free Join today!
    20 Mar 2014, 07:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs